Monte Rosa Therapeutics (GLUE) Assets Average (2021 - 2026)

Monte Rosa Therapeutics' Assets Average history runs 6 years deep, the most recent figure standing at $592.5 million for Q1 2026.

• In Q1 2026, Assets Average rose 42.45% year-over-year to $592.5 million; the TTM figure through Mar 2026 stood at $592.5 million (up 42.45% YoY), while the FY2025 annual figure was $443.7 million, up 19.52% from the prior year.
• Assets Average was $592.5 million for Q1 2026 at Monte Rosa Therapeutics, up from $454.2 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $592.5 million in Q1 2026 to a low of $265.4 million in Q3 2023.
• Historically, Assets Average has averaged $360.7 million across 5 years, with a median of $355.5 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Assets Average slipped 26.56% in 2023, then surged 45.82% in 2025.
• A 5-year view of Assets Average shows it stood at $350.0 million in 2022, then declined by 20.59% to $277.9 million in 2023, then jumped by 35.61% to $376.9 million in 2024, then advanced by 20.52% to $454.2 million in 2025, then jumped by 30.44% to $592.5 million in 2026.
• The last three Assets Average figures came in at $592.5 million (Q1 2026), $454.2 million (Q4 2025), and $409.7 million (Q3 2025), per Business Quant data.